Does the media prefer IDYA or SMMT?

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 2 mentions for Summit Therapeutics. IDEAYA Biosciences' average media sentiment score of 0.82 beat Summit Therapeutics' score of 0.36 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BBIO or IDYA?

In the previous week, BridgeBio Pharma had 6 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 13 mentions for BridgeBio Pharma and 7 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.82 beat BridgeBio Pharma's score of 0.49 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IDEAYA Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IDYA or HALO?

In the previous week, Halozyme Therapeutics had 19 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 26 mentions for Halozyme Therapeutics and 7 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.82 beat Halozyme Therapeutics' score of 0.64 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 11 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IDYA or MDGL?

In the previous week, IDEAYA Biosciences had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 6 mentions for Madrigal Pharmaceuticals. IDEAYA Biosciences' average media sentiment score of 0.82 beat Madrigal Pharmaceuticals' score of 0.25 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BMRN or IDYA?

In the previous week, IDEAYA Biosciences had 1 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 6 mentions for BioMarin Pharmaceutical. IDEAYA Biosciences' average media sentiment score of 0.82 beat BioMarin Pharmaceutical's score of 0.16 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IDEAYA Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IDEAYA Biosciences (IDYA) Competitors

$36.11 +0.05 (+0.14%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$36.13 +0.02 (+0.06%)

As of 10/9/2026 07:30 PM Eastern

Compare

IDYA vs. SMMT, BBIO, HALO, MDGL, and BMRN

Should you buy IDEAYA Biosciences stock or one of its competitors? IDEAYA Biosciences's main competitors and comparable companies include Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IDEAYA Biosciences compare to Summit Therapeutics?

IDEAYA Biosciences (NASDAQ:IDYA) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 2 mentions for Summit Therapeutics. IDEAYA Biosciences' average media sentiment score of 0.82 beat Summit Therapeutics' score of 0.36 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences currently has a consensus target price of $52.69, indicating a potential upside of 45.92%. Summit Therapeutics has a consensus target price of $28.61, indicating a potential upside of 62.64%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

IDEAYA Biosciences has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Summit Therapeutics	N/A	-168.94%	-141.92%

IDEAYA Biosciences has higher revenue and earnings than Summit Therapeutics. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.51	-$113.70M	-$1.94	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Summary

IDEAYA Biosciences beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, BridgeBio Pharma had 6 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 13 mentions for BridgeBio Pharma and 7 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.82 beat BridgeBio Pharma's score of 0.49 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEAYA Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences has lower revenue, but higher earnings than BridgeBio Pharma. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.44	-$724.93M	-$3.57	N/A
IDEAYA Biosciences	$218.71M	14.51	-$113.70M	-$1.94	N/A

BridgeBio Pharma presently has a consensus target price of $105.42, suggesting a potential upside of 61.32%. IDEAYA Biosciences has a consensus target price of $52.69, suggesting a potential upside of 45.92%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

IDEAYA Biosciences has a net margin of -75.93% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

Summary

BridgeBio Pharma beats IDEAYA Biosciences on 11 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Halozyme Therapeutics?

IDEAYA Biosciences (NASDAQ:IDYA) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Halozyme Therapeutics had 19 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 26 mentions for Halozyme Therapeutics and 7 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.82 beat Halozyme Therapeutics' score of 0.64 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	11 Very Positive mention(s)	8 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences presently has a consensus target price of $52.69, indicating a potential upside of 45.92%. Halozyme Therapeutics has a consensus target price of $94.00, indicating a potential downside of 14.87%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe IDEAYA Biosciences is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Halozyme Therapeutics has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.51	-$113.70M	-$1.94	N/A
Halozyme Therapeutics	$1.40B	8.97	$316.89M	$3.35	32.96

Halozyme Therapeutics has a net margin of 24.86% compared to IDEAYA Biosciences' net margin of -75.93%. Halozyme Therapeutics' return on equity of 260.98% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Halozyme Therapeutics	24.86%	260.98%	23.91%

IDEAYA Biosciences has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Halozyme Therapeutics beats IDEAYA Biosciences on 9 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Madrigal Pharmaceuticals?

IDEAYA Biosciences (NASDAQ:IDYA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

IDEAYA Biosciences has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.51	-$113.70M	-$1.94	N/A
Madrigal Pharmaceuticals	$958.40M	11.37	-$288.28M	-$12.89	N/A

Madrigal Pharmaceuticals has a net margin of -25.32% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

IDEAYA Biosciences presently has a consensus price target of $52.69, indicating a potential upside of 45.92%. Madrigal Pharmaceuticals has a consensus price target of $710.20, indicating a potential upside of 50.55%. Given Madrigal Pharmaceuticals' higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, IDEAYA Biosciences had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 6 mentions for Madrigal Pharmaceuticals. IDEAYA Biosciences' average media sentiment score of 0.82 beat Madrigal Pharmaceuticals' score of 0.25 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the broader market.

Summary

IDEAYA Biosciences beats Madrigal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioMarin Pharmaceutical presently has a consensus target price of $87.82, indicating a potential upside of 60.28%. IDEAYA Biosciences has a consensus target price of $52.69, indicating a potential upside of 45.92%. Given BioMarin Pharmaceutical's higher probable upside, research analysts plainly believe BioMarin Pharmaceutical is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.65
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

BioMarin Pharmaceutical has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.29	$348.90M	$0.37	148.08
IDEAYA Biosciences	$218.71M	14.51	-$113.70M	-$1.94	N/A

BioMarin Pharmaceutical has a net margin of 2.14% compared to IDEAYA Biosciences' net margin of -75.93%. BioMarin Pharmaceutical's return on equity of 5.32% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

BioMarin Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

In the previous week, IDEAYA Biosciences had 1 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 6 mentions for BioMarin Pharmaceutical. IDEAYA Biosciences' average media sentiment score of 0.82 beat BioMarin Pharmaceutical's score of 0.16 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEAYA Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioMarin Pharmaceutical beats IDEAYA Biosciences on 12 of the 17 factors compared between the two stocks.

Get IDEAYA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDYA vs. The Competition

Export

Metric	IDEAYA Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.17B	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-18.61	13.62	275.30	26.16
Price / Sales	14.51	1,234.33	635.97	107.53
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	3.09	17.17	11.22	6.33
Net Income	-$113.70M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-3.35%	-1.34%	-0.89%	-1.40%
1 Month Performance	-3.58%	-8.45%	-4.42%	-3.47%
1 Year Performance	37.61%	14.02%	7.03%	1.18%

IDEAYA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDYA IDEAYA Biosciences	3.8877 of 5 stars	$36.11 +0.1%	$52.69 +45.9%	+34.8%	$3.17B	$218.71M	N/A	145	News Coverage Insider Trade
SMMT Summit Therapeutics	2.5958 of 5 stars	$16.91 +3.2%	$28.45 +68.3%	-22.3%	$13.08B	N/A	N/A	265	Positive News
BBIO BridgeBio Pharma	3.7585 of 5 stars	$65.80 -0.3%	$102.61 +55.9%	+19.3%	$12.90B	$502.08M	N/A	839	Analyst Forecast
HALO Halozyme Therapeutics	3.454 of 5 stars	$110.40 -1.0%	$91.20 -17.4%	+69.6%	$12.66B	$1.66B	32.96	423	Trending News Analyst Forecast Insider Trade
MDGL Madrigal Pharmaceuticals	3.1748 of 5 stars	$503.96 -1.1%	$710.20 +40.9%	+10.1%	$11.77B	$958.40M	N/A	915

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDYA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. SMMT, BBIO, HALO, MDGL, and BMRN

How does IDEAYA Biosciences compare to Summit Therapeutics?

Summary

How does IDEAYA Biosciences compare to BridgeBio Pharma?

Summary

How does IDEAYA Biosciences compare to Halozyme Therapeutics?

Summary

How does IDEAYA Biosciences compare to Madrigal Pharmaceuticals?

Summary

How does IDEAYA Biosciences compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. SMMT, BBIO, HALO, MDGL, and BMRN

How does IDEAYA Biosciences compare to Summit Therapeutics?

Does the media prefer IDYA or SMMT?

Do analysts rate IDYA or SMMT?

Do insiders & institutionals believe in IDYA or SMMT?

Which has more risk & volatility, IDYA or SMMT?

Is IDYA or SMMT more profitable?

Which has higher earnings & valuation, IDYA or SMMT?

Summary

How does IDEAYA Biosciences compare to BridgeBio Pharma?

Does the media favor BBIO or IDYA?

Which has better earnings and valuation, BBIO or IDYA?

Do analysts prefer BBIO or IDYA?

Is BBIO or IDYA more profitable?

Do insiders and institutionals hold more shares of BBIO or IDYA?

Which has more risk & volatility, BBIO or IDYA?

Summary

How does IDEAYA Biosciences compare to Halozyme Therapeutics?

Does the media prefer IDYA or HALO?

Do analysts prefer IDYA or HALO?

Which has better valuation & earnings, IDYA or HALO?

Is IDYA or HALO more profitable?

Which has more risk and volatility, IDYA or HALO?

Do institutionals and insiders believe in IDYA or HALO?

Summary

How does IDEAYA Biosciences compare to Madrigal Pharmaceuticals?

Which has better valuation and earnings, IDYA or MDGL?

Is IDYA or MDGL more profitable?

Do analysts recommend IDYA or MDGL?

Do insiders and institutionals believe in IDYA or MDGL?

Does the media refer more to IDYA or MDGL?

Which has more volatility & risk, IDYA or MDGL?

Summary

How does IDEAYA Biosciences compare to BioMarin Pharmaceutical?

Do insiders & institutionals believe in BMRN or IDYA?

Do analysts rate BMRN or IDYA?

Which has preferable valuation and earnings, BMRN or IDYA?

Is BMRN or IDYA more profitable?

Which has more volatility & risk, BMRN or IDYA?

Does the media prefer BMRN or IDYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools